


This listing of claims will replace all prior versions and listings of claims in the application:

1. **(Currently Amended)** A method for enhancing the bioavailability of an orally administered therapeutically active compound of the formula (I)



or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof ~~metabolite thereof~~ selected from the group consisting of TORE VI (4-hydroxy(deaminohydroxy)toremifene), TORE VII (4,4'-dihydroxy-(deaminohydroxy)toremifene), TORE XVIII ((deaminocarboxy)toremifene), TORE VIII (4-hydroxy(deaminocarboxy)toremifene) and TORE XIII (toremifene monophenol), wherein said compound is administered orally to the an individual in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids, being taken shortly before, during or after administering the compound to enhance bioavailability of the compound.

2. **(Original)** The method according to claim 1 wherein compound (I) is ospemifene.

3. **(Original)** The method according to claim 1, wherein the compound is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake.

4. **(Previously Presented)** The method according to claim 3 wherein the compound is administered within one hour after the food intake was started.

5. **(Original)** The method according to claim 4 wherein the compound is administered at a time point which is no later than 0.5 hour after starting the food intake.


6. **(Canceled)**

7. **(Previously Presented)** The method according to claim 1 wherein the compound is used for treatment of osteoporosis.

8. **(Previously Presented)** The method according to claim 1 wherein the compound is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy.

9. **(Original)** The method according to claim 8 wherein the symptoms related to atrophy are urinary symptoms or vaginal symptoms.


10. **(Currently Amended)** The method according to claim 7, wherein the therapeutically active compound is the Z-isomer of a compound of formula (I)



—and wherein the dosage amount is from 30 to 90 mg/day.

11. **(Previously Presented)** The method according to claim 10, wherein the dosage amount is 60 mg.

12. **(Previously Presented)** The method according to claim 8, wherein the therapeutically active compound is the Z-isomer of a compound of formula (I)



and wherein the dosage amount is from 30 to 90 mg/day.

13. **(Previously Presented)** The method according to claim 12, wherein the dosage amount is 60 mg.